|
시장보고서
상품코드
2042654
지속형 주사제 약물전달 시장 규모 및 예측(2021-2034년), 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 제제 포장별, 치료 용도별, 투여 경로별, 지역별Long-Term Injectable Drug Delivery Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Formulation Packaging, Therapeutic Application, Route of Administration and Geography |
||||||
지속형 주사제 약물전달 시장은 2025년 70억 7,000만 달러에서 2034년까지 152억 1,000만 달러에 달할 것으로 예측됩니다. 시장은 2026년부터 2034년까지 CAGR 8.9%를 기록할 것으로 추정됩니다. 시장 성장을 주도하는 주요 요인으로는 장기적인 약물 치료가 필요한 만성 질환 및 정신 질환의 유병률 증가, 약물 전달 기술의 발전, 그리고 복약 순응도 향상 및 투여 빈도 감소에 대한 수요 증가를 들 수 있으며, 이러한 요인들이 지속성 주사제 약물 전달의 활용을 촉진하고 있습니다. 또한, 자가면역 질환 및 종양학 분야에서 지속형 바이오의약품과 바이오시밀러에 대한 수요 증가가 예측 기간 동안 시장을 견인할 것으로 전망됩니다. 그러나 개발 및 제조의 높은 복잡성은 시장의 장벽 중 하나로 작용하고 있습니다.
지속형 주사제 약물전달 기술의 발전은 장기간에 걸쳐 정확하고 지속적인 약물 방출을 가능하게함으로써 약물 치료에 혁명을 일으켰습니다. 첨단 약물전달 시스템은 펩타이드, 바이오의약품 및 새로운 mRNA 기반 치료제와 같은 복잡한 분자를 처리하면서 안정적인 혈장 농도를 유지합니다. 주요 혁신 기술로는 생분해성 폴리(젖산-코-글리콜산(PLGA) 폴리머를 이용한 마이크로캡슐화를 통한 마이크로스피어 형성, 안정성과 표적화를 향상시키는 나노입자, 주사 후 고형화하여 국소 저장소를 형성하는 기술, 수개월에 걸친 방출을 가능하게 하는 초장시간 지속형 현탁액 등이 있습니다. 서스펜션 등을 들 수 있습니다. 이러한 시스템은 민감한 화합물을 급속한 분해로부터 보호하고, 제로차 또는 제어된 방출 동역학을 보장함으로써 기존 경구 제제 및 단시간 작용 주사제의 한계를 극복하고 있습니다.
FDA가 승인한 대표적인 사례는 이러한 진전을 여실히 보여주고 있습니다. PLGA 마이크로스피어 제제인 루프론 디포(류프로리드 아세테이트)는 전립선암과 자궁내막증 치료에 있어 최대 6개월 동안 펩타이드 호르몬 작용제를 방출합니다. 이는 마이크로캡슐화를 통해 투여 빈도를 줄이면서 성선자극호르몬 분비 호르몬의 억제를 안정적으로 달성할 수 있다는 것을 입증한 것입니다. 리스페달 콘스타는 리스페리돈에 PLGA 마이크로스피어를 적용하여 정신분열증 관리를 위해 한 달에 한 번 근육 내 투여를 실현하여 매일 경구투여 대비 복약순응도를 향상시켰습니다. 엘리가드(류프로리드)와 같은 국소형 저장소 제제는 주사 후 피하 임플란트를 형성하고 고형화하여 방출을 조절하는 방식입니다. 나노입자 및 나노 서스펜션 기술은 인베가 트린자(팔리페리돈 팔미틴산염)와 같은 제품을 뒷받침하고 있습니다. 이는 나노결정공학을 통해 흡수 지속성을 확보하여 정신질환에 대해 3개월마다 투여할 수 있는 초장시간 작용형 제제입니다.
이러한 플랫폼은 바이오의약품에도 적용되어 지질나노입자(LNP)를 통해 mRNA 응용을 지원하고 있습니다. LNP는 백신이나 치료제용 단백질이나 mRNA와 같은 크고 깨지기 쉬운 분자를 보호하고 전달하여 세포 내로 흡수 및 지속적 발현을 가능하게 합니다. 바이오의약품과 mRNA 구조체에서 더 긴 작용시간과 광범위한 적용 가능성을 위한 연구가 진행됨에 따라, 이러한 혁신 기술은 신뢰할 수 있는 장기 약물 노출이 필요한 만성 질환에 대해 환자 편의성 향상, 치료 효과 강화 및 치료 옵션의 확장을 가져올 것으로 기대됩니다. 기대됩니다.
기업 비교 분석에서는 제품 포트폴리오(제품 만족도, 제품 기능, 가용성), 최근 동향(인수합병, 신제품 출시 및 개선, 투자 및 자금 조달, 수상, 계약, 제휴 및 파트너십, 평가, 사업 확장), 지리적 확장에 따라 지속형 주사제 약물전달 시장을 평가하고 분류합니다. 이를 통해 의사결정을 지원하고 경쟁 상황을 더 잘 이해할 수 있습니다. 이 보고서는 세계 지속형 주사제 약물전달 시장의 주요 벤더들의 최근 주요 동향과 혁신에 대해 심층적으로 분석합니다. 주요 시장 기업으로는 Becton Dickinson and Co, Schott AG, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Terumo Corp, SHL Medical, Ypsomed Holding AG, Owen Mumford Ltd, Owen Mumford Ltd, Aptar Group Inc. Ypsomed Holding AG, Owen Mumford Ltd, AptarGroup Inc 등이 있습니다.
제형 포장(Ready-to-Use) 측면에서 지속형 주사제 약물전달 시장은 앰플, 바이알, 카트리지, 병으로 분류됩니다. 2025년에는 바이알 부문이 더 큰 시장 점유율을 차지했습니다. 바이알은 생물학적 제제 및 백신 제품을 포함한 다양한 주사제를 보관할 수 있어 제제 포장 부문에서 강력한 성장세를 보이고 있습니다. 이 제품들은 우수한 화학적 내구성과 오염으로부터의 보호 기능을 제공합니다.
치료 용도별로 지속형 주사제 약물전달 시장은 당뇨병, 종양학, 자가면역질환, 심혈관질환, 감염질환, 통증 관리, 기타 치료 용도로 분류됩니다. 2025년에는 당뇨병 부문이 더 큰 시장 점유율을 차지했습니다. 전 세계 당뇨병 유병률 증가, 지속형 인슐린 및 GLP-1 요법에 대한 높은 수요, 환자의 복약 순응도 향상, 투여 빈도 감소, 서방형 제제의 지속적인 혁신 등이 이 부문의 성장을 견인하고 있습니다.
투여 경로 측면에서 장기지속형 주사제 전달 시장은 피하, 근육 내, 정맥 내, 기타 투여 경로로 분류됩니다. 2025년에는 피하 투여 부문이 더 큰 시장 점유율을 차지했습니다. 자가 투여의 용이성, 임상적 감독 필요성 감소, 환자 편의성 향상, 생물학적 제제와의 호환성, 웨어러블 및 자동 주사기 시스템의 보급 확대 등이 피하 투여에 대한 강력한 지지를 뒷받침하고 있습니다.
사용 방법의 관점에서 지속형 주사제 약물전달 시장은 일회용 주사기와 재사용 가능한 주사기로 나뉩니다. 2025년에는 일회용 주사기 부문이 더 큰 시장 점유율을 차지했습니다. 편의성, 교차 오염 위험 감소, 유지보수 불필요, 사용 편의성, 홈케어 솔루션에 대한 수요 증가 등이 일회용 주사기 시스템의 채택 확대에 기여하고 있습니다.
최종사용자별로 보면 장기지속형 주사제 전달 시장은 제약 및 바이오제약 기업, CMO(위탁생산업체), CDMO(위탁개발 및 생산업체)로 분류됩니다. 2025년에는 제약 및 바이오 제약 기업 부문이 더 큰 시장 점유율을 차지했습니다. 강력한 R&D 역량, 풍부한 의약품 파이프라인, 장기지속형 제제에 대한 막대한 투자, 탄탄한 제조 인프라, 전략적 제휴를 통해 제약 및 바이오 제약 기업은 시장 도입 및 상용화를 주도하고 있습니다.
지속형 주사제 약물전달 시장에서 사업을 전개하는 기업들은 다양한 유기적 및 무기적 전략을 채택하고 있습니다. 유기적 전략에는 주로 제품 출시와 승인 등이 포함됩니다. 시장에서 볼 수 있는 무기적 성장 전략으로는 인수, 제휴, 파트너십 등이 있습니다. 이러한 성장 전략을 통해 시장 참여자들은 사업을 확장하고, 지리적 입지를 강화하며, 전체 시장 성장에 기여할 수 있습니다. 또한, 인수 및 파트너십을 통해 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 기여했습니다. 지속형 주사제 약물전달 시장의 주요 업체들의 주요 동향은 다음과 같습니다.
2026년 3월, 첨단 약물전달 솔루션의 세계 리더인 SHL Medical AG는 과학 분야의 세계 리더인 Thermo Fisher Scientific Inc.와의 전략적 제휴를 발표했습니다. 이번 제휴를 통해 미국 뉴저지 주 리지필드에 위치한 Thermo Fisher의 시설에서 무균 충전, 마감 및 장치 최종 조립에 대한 엔드 투 엔드 서비스를 제공하게 됩니다.
2026년 1월, BD와 입소메드는 입소메드의 자동 주사기 플랫폼 'YpsoMate 5.5'에 대응하는 5.5mL 'BD Neopak XtraFlow' 유리 프리필드 시린지 개발을 위한 협력 강화를 발표했습니다. 이 혁신적인 노력은 유동 효율을 높이고 주입 시간을 단축하여 대용량 및 고점도 생물학적 제제의 자가 주입을 지원하는 것을 목표로 합니다. 이러한 움직임은 복잡한 치료법에서 환자가 쉽게 사용할 수 있는 자가 투여에 대한 수요 증가에 대응하기 위한 것입니다. 개발용 및 타당성 평가용 샘플은 2026년 중반까지 제공될 예정입니다.
목차
제1장 주요 요약
제2장 지속형 주사제 약물전달 시장 전망
제3장 경쟁 구도
제4장 지속형 주사제 약물전달 시장 : 주요 업계 역학
제5장 지속형 주사제 약물전달 시장 : 세계 시장 분석
제6장 지속형 주사제 약물전달 시장 매출 분석 : 제제 포장(Ready-to-use)별
제7장 지속형 주사제 약물전달 시장 매출 분석 : 치료 용도별
제8장 지속형 주사제 약물전달 시장 매출 분석 : 투여 경로별
제9장 지속형 주사제 약물전달 시장 매출 분석 : 사용성별
제10장 지속형 주사제 약물전달 시장 매출 분석 : 최종사용자별
제11장 지속형 주사제 약물전달 시장 : 지역별 분석
제12장 지속형 주사제 약물전달 시장 업계 상황
제13장 지속형 주사제 약물전달 시장 : 주요 기업 개요
제14장 기타 분석 대상 기업 리스트
제15장 부록
KSM 26.06.05The long-term injectable drug delivery market is projected to reach US$ 15.21 billion by 2034 from US$ 7.07 billion in 2025. The market is estimated to register a CAGR of 8.9% during 2026-2034. Major factors driving market growth include the increasing prevalence of chronic and psychiatric disorders requiring long-term pharmacotherapy, advancements in drug delivery technologies, and the rising need to improve medication adherence and reduce dosing frequency that promote long-term injectable drug delivery utilization. Further, increased demand for long-acting biologics and biosimilars in autoimmune and oncology will likely boost the market during the forecast period. However, high complexity of development and manufacturing are among the deterrents of market.
Technological advancements in long-term injectable drug delivery have revolutionized pharmacotherapy by enabling precise, sustained drug release over extended periods. Advanced drug delivery systems maintain stable plasma levels while accommodating complex molecules such as peptides, biologics, and emerging mRNA-based therapies. Key innovations include microencapsulation using biodegradable poly(lactic-co-glycolic acid) (PLGA) polymers to form microspheres, nanoparticles for enhanced stability and targeting, in-situ forming depots that solidify post-injection, and ultra-long-acting suspensions that provide release for months. These systems overcome limitations of traditional oral or short-acting injectables by protecting sensitive compounds from rapid degradation and ensuring zero-order or controlled release kinetics.
Prominent FDA-approved examples illustrate this progress. Lupron Depot (leuprolide acetate), a PLGA microsphere formulation, delivers the peptide hormone agonist for up to six months in prostate cancer and endometriosis treatment, demonstrating how microencapsulation achieves consistent gonadotropin-releasing hormone suppression with reduced dosing frequency. Risperdal Consta employs PLGA microspheres for risperidone, providing monthly intramuscular release for schizophrenia management and improving adherence over daily orals. In-situ forming depots such as Eligard (leuprolide) create a subcutaneous implant upon injection, solidifying to control release. Nanoparticle and nanosuspension technologies power products such as Invega Trinza (paliperidone palmitate), an ultra-long-acting formulation offering three-month dosing for psychiatric disorders via nanocrystal engineering that ensures prolonged absorption.
These platforms also extend to biologics and support mRNA applications through lipid nanoparticles (LNPs), which protect and deliver large, fragile molecules such as proteins or mRNA for vaccines and therapeutics, enabling cellular uptake and sustained expression. As research advances toward even longer durations and broader applicability for biologics and mRNA constructs, these innovations promise greater patient convenience, enhanced therapeutic efficacy, and expanded treatment options for chronic conditions requiring reliable, long-term drug exposure.
The comparative company analysis evaluates and categorizes the Long-Term Injectable Drug Delivery market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Long-Term Injectable Drug Delivery market. The key market players are Becton Dickinson and Co, Schott AG, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc., Terumo Corp, SHL Medical, Ypsomed Holding AG, Owen Mumford Ltd, and AptarGroup Inc.
In terms of formulation packaging (ready-to-use), the long-term injectable drug delivery market is bifurcated into ampoules, vials, cartridges, bottles. The vials segment held a larger market share in 2025. Vials are experiencing strong growth in the formulation packaging segment because they can store diverse injectable medications, which include biologic and vaccine products. The products provide exceptional chemical durability and protection from contamination.
In terms of therapeutic application, the long-term injectable drug delivery market is bifurcated diabetes, oncology, auto-immune disorders, cardiovascular diseases, infectious diseases, pain management, other therapeutic application. The diabetes segment held a larger market share in 2025. Rising global diabetes prevalence, strong demand for long-acting insulin and GLP-1 therapies, improved patient adherence, reduced dosing frequency, and continuous innovation in sustained-release formulations drive segment growth.
In terms of route of administration, the long-term injectable drug delivery market is bifurcated into sub-cutaneous, intramuscular, intravenous, other route of administration. The sub-cutaneous segment held a larger market share in 2025. Ease of self-administration, reduced need for clinical supervision, improved patient comfort, compatibility with biologics, and growing adoption of wearable and auto-injector systems support strong preference for subcutaneous delivery.
In terms of route of usability, the long-term injectable drug delivery market is bifurcated into disposable injectors, re-usable injectors. The disposable injectors segment held a larger market share in 2025. Convenience, reduced risk of cross-contamination, no maintenance requirements, ease of use, and increasing demand for home-based care solutions contribute to higher adoption of disposable injector systems.
Based on end user, the long-term injectable drug delivery market is categorized into pharmaceutical and biopharma companies, CMOs and CDMOs. The pharmaceutical and biopharma companies segment held a larger share of the market in 2025. Strong R&D capabilities, extensive drug pipelines, high investment in long-acting formulations, established manufacturing infrastructure, and strategic collaborations enable pharmaceutical and biopharma companies to lead market adoption and commercialization.
Companies operating in the long-term injectable drug delivery market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key Long-Term Injectable Drug Delivery market players are listed below.
In March 2026, SHL Medical AG, the global leader in advanced drug delivery solutions, announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science. The collaboration will provide end-to-end offering of sterile fill-finish and device final assembly at Thermo Fisher?s site in Ridgefield, New Jersey, USA.
In January 2026, BD and Ypsomed announced an enhanced collaboration to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe compatible with Ypsomed's YpsoMate 5.5 autoinjector platform. This innovation aims to support large-volume, high-viscosity biologic self-injection by improving flow efficiency and reducing injection time. The move responds to growing demand for patient-friendly self-administration of complex therapies. Development and feasibility samples are expected by mid-2026.
Table Of Contents
1. Executive Summary
- 1.1 Analyst Market Outlook
- 1.2 Market Attractiveness
2. Long-Term Injectable Drug Delivery Market Landscape
- 2.1 Overview
- 2.2 Value Chain Analysis
- 2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
- 2.4 Porter's Five Force Analysis
- 2.5 PEST Analysis
- 2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
- 2.6.1 Import-Export Analysis for Key Countries
- 2.7 Impact of Artificial Intelligence (AI)
- 2.8 Product or Technology Roadmap
- 2.9 Sustainability and ESG Trends
- 2.10 Patent Analysis
- 2.11 Regulatory Framework
3. Competitive Landscape
- 3.1 Company Benchmarking by Key Players
- 3.2 Market Share Analysis, 2025 - By Key Players
- 3.3 Market Concentration
4. Long-Term Injectable Drug Delivery Market - Key Industry Dynamics
- 4.1 Market Drivers
- 4.2 Market Restraints
- 4.3 Market Opportunities
- 4.4 Future Trends
- 4.5 Impact of Drivers and Restraints
5. Long-Term Injectable Drug Delivery Market - Global Market Analysis
- 5.1 Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021-2034
- 5.2 Long-Term Injectable Drug Delivery Market Forecast and Analysis
6. Long-Term Injectable Drug Delivery Market Revenue Analysis - Formulation Packaging (ready-to-use)
- 6.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
- 6.1.1.1 Overview
- 6.1.1.2 Ampoules: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.2 Vials
- 6.1.2.1 Overview
- 6.1.2.2 Vials: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.3 Cartridges
- 6.1.3.1 Overview
- 6.1.3.2 Cartridges: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.4 Bottles
- 6.1.4.1 Overview
- 6.1.4.2 Bottles: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.1 Ampoules
7. Long-Term Injectable Drug Delivery Market Revenue Analysis - Therapeutic Application
- 7.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Therapeutic Application
- 7.1.1 Diabetes
- 7.1.1.1 Overview
- 7.1.1.2 Diabetes: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.2 Oncology
- 7.1.2.1 Overview
- 7.1.2.2 Oncology: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
- 7.1.3.1 Overview
- 7.1.3.2 Auto-Immune Disorders: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
- 7.1.4.1 Overview
- 7.1.4.2 Cardiovascular Diseases: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.5 Infectious Diseases
- 7.1.5.1 Overview
- 7.1.5.2 Infectious Diseases: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.6 Pain Management
- 7.1.6.1 Overview
- 7.1.6.2 Pain Management: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.7 Others
- 7.1.7.1 Overview
- 7.1.7.2 Others: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.1 Diabetes
8. Long-Term Injectable Drug Delivery Market Revenue Analysis - Route Of Administration
- 8.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
- 8.1.1.1 Overview
- 8.1.1.2 Subcutaneous: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.2 Intramuscular
- 8.1.2.1 Overview
- 8.1.2.2 Intramuscular: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.3 Intravenous
- 8.1.3.1 Overview
- 8.1.3.2 Intravenous: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.4 Others
- 8.1.4.1 Overview
- 8.1.4.2 Others: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.1 Subcutaneous
9. Long-Term Injectable Drug Delivery Market Revenue Analysis - Usability
- 9.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Usability
- 9.1.1 Disposable Injectors
- 9.1.1.1 Overview
- 9.1.1.2 Disposable Injectors: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 9.1.2 Re-usable Injectors
- 9.1.2.1 Overview
- 9.1.2.2 Re-usable Injectors: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 9.1.1 Disposable Injectors
10. Long-Term Injectable Drug Delivery Market Revenue Analysis - End User
- 10.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
- 10.1.1.1 Overview
- 10.1.1.2 Pharmaceutical and Biopharma Companies: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
- 10.1.2.1 Overview
- 10.1.2.2 CMOs and CDMOs: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 10.1.1 Pharmaceutical and Biopharma Companies
11. Long-Term Injectable Drug Delivery Market - Geographical Analysis
- 11.1 North America
- 11.1.1 North America Long-Term Injectable Drug Delivery Market Overview
- 11.1.2 North America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.1.3 North America: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.1.3.1 Formulation Packaging (ready-to-use)
- 11.1.3.2 Therapeutic Application
- 11.1.3.3 Route Of Administration
- 11.1.3.4 Usability
- 11.1.3.5 End User
- 11.1.4 North America: Long-Term Injectable Drug Delivery Market Breakdown by Countries
- 11.1.4.1 United States Market
- 11.1.4.1.1 United States: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.1.4.1.2 United States: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.1.4.1.2.1 Formulation Packaging (ready-to-use)
- 11.1.4.1.2.2 Therapeutic Application
- 11.1.4.1.2.3 Route Of Administration
- 11.1.4.1.2.4 Usability
- 11.1.4.1.2.5 End User
- 11.1.4.2 Canada Market
- 11.1.4.2.1 Canada: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.1.4.2.2 Canada: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.1.4.2.2.1 Formulation Packaging (ready-to-use)
- 11.1.4.2.2.2 Therapeutic Application
- 11.1.4.2.2.3 Route Of Administration
- 11.1.4.2.2.4 Usability
- 11.1.4.2.2.5 End User
- 11.1.4.3 Mexico Market
- 11.1.4.3.1 Mexico: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.1.4.3.2 Mexico: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.1.4.3.2.1 Formulation Packaging (ready-to-use)
- 11.1.4.3.2.2 Therapeutic Application
- 11.1.4.3.2.3 Route Of Administration
- 11.1.4.3.2.4 Usability
- 11.1.4.3.2.5 End User
- 11.1.4.1 United States Market
- 11.2 Europe
- 11.2.1 Europe Long-Term Injectable Drug Delivery Market Overview
- 11.2.2 Europe: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.3 Europe: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.3.1 Formulation Packaging (ready-to-use)
- 11.2.3.2 Therapeutic Application
- 11.2.3.3 Route Of Administration
- 11.2.3.4 Usability
- 11.2.3.5 End User
- 11.2.4 Europe: Long-Term Injectable Drug Delivery Market Breakdown by Countries
- 11.2.4.1 Germany Market
- 11.2.4.1.1 Germany: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.1.2 Germany: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.1.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.1.2.2 Therapeutic Application
- 11.2.4.1.2.3 Route Of Administration
- 11.2.4.1.2.4 Usability
- 11.2.4.1.2.5 End User
- 11.2.4.2 United Kingdom Market
- 11.2.4.2.1 United Kingdom: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.2.2 United Kingdom: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.2.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.2.2.2 Therapeutic Application
- 11.2.4.2.2.3 Route Of Administration
- 11.2.4.2.2.4 Usability
- 11.2.4.2.2.5 End User
- 11.2.4.3 France Market
- 11.2.4.3.1 France: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.3.2 France: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.3.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.3.2.2 Therapeutic Application
- 11.2.4.3.2.3 Route Of Administration
- 11.2.4.3.2.4 Usability
- 11.2.4.3.2.5 End User
- 11.2.4.4 Spain Market
- 11.2.4.4.1 Spain: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.4.2 Spain: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.4.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.4.2.2 Therapeutic Application
- 11.2.4.4.2.3 Route Of Administration
- 11.2.4.4.2.4 Usability
- 11.2.4.4.2.5 End User
- 11.2.4.5 Italy Market
- 11.2.4.5.1 Italy: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.5.2 Italy: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.5.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.5.2.2 Therapeutic Application
- 11.2.4.5.2.3 Route Of Administration
- 11.2.4.5.2.4 Usability
- 11.2.4.5.2.5 End User
- 11.2.4.6 Rest of Europe Market
- 11.2.4.6.1 Rest of Europe: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.4.6.2 Rest of Europe: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.2.4.6.2.1 Formulation Packaging (ready-to-use)
- 11.2.4.6.2.2 Therapeutic Application
- 11.2.4.6.2.3 Route Of Administration
- 11.2.4.6.2.4 Usability
- 11.2.4.6.2.5 End User
- 11.2.4.1 Germany Market
- 11.3 Asia Pacific
- 11.3.1 Asia Pacific Long-Term Injectable Drug Delivery Market Overview
- 11.3.2 Asia Pacific: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.3 Asia Pacific: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.3.1 Formulation Packaging (ready-to-use)
- 11.3.3.2 Therapeutic Application
- 11.3.3.3 Route Of Administration
- 11.3.3.4 Usability
- 11.3.3.5 End User
- 11.3.4 Asia Pacific: Long-Term Injectable Drug Delivery Market Breakdown by Countries
- 11.3.4.1 China Market
- 11.3.4.1.1 China: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.1.2 China: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.1.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.1.2.2 Therapeutic Application
- 11.3.4.1.2.3 Route Of Administration
- 11.3.4.1.2.4 Usability
- 11.3.4.1.2.5 End User
- 11.3.4.2 Japan Market
- 11.3.4.2.1 Japan: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.2.2 Japan: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.2.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.2.2.2 Therapeutic Application
- 11.3.4.2.2.3 Route Of Administration
- 11.3.4.2.2.4 Usability
- 11.3.4.2.2.5 End User
- 11.3.4.3 India Market
- 11.3.4.3.1 India: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.3.2 India: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.3.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.3.2.2 Therapeutic Application
- 11.3.4.3.2.3 Route Of Administration
- 11.3.4.3.2.4 Usability
- 11.3.4.3.2.5 End User
- 11.3.4.4 Australia Market
- 11.3.4.4.1 Australia: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.4.2 Australia: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.4.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.4.2.2 Therapeutic Application
- 11.3.4.4.2.3 Route Of Administration
- 11.3.4.4.2.4 Usability
- 11.3.4.4.2.5 End User
- 11.3.4.5 South Korea Market
- 11.3.4.5.1 South Korea: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.5.2 South Korea: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.5.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.5.2.2 Therapeutic Application
- 11.3.4.5.2.3 Route Of Administration
- 11.3.4.5.2.4 Usability
- 11.3.4.5.2.5 End User
- 11.3.4.6 Rest of Asia Pacific Market
- 11.3.4.6.1 Rest of Asia Pacific: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.4.6.2 Rest of Asia Pacific: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.3.4.6.2.1 Formulation Packaging (ready-to-use)
- 11.3.4.6.2.2 Therapeutic Application
- 11.3.4.6.2.3 Route Of Administration
- 11.3.4.6.2.4 Usability
- 11.3.4.6.2.5 End User
- 11.3.4.1 China Market
- 11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Overview
- 11.4.2 Middle East and Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.3 Middle East and Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.4.3.1 Formulation Packaging (ready-to-use)
- 11.4.3.2 Therapeutic Application
- 11.4.3.3 Route Of Administration
- 11.4.3.4 Usability
- 11.4.3.5 End User
- 11.4.4 Middle East and Africa: Long-Term Injectable Drug Delivery Market Breakdown by Countries
- 11.4.4.1 Saudi Arabia Market
- 11.4.4.1.1 Saudi Arabia: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.4.1.2 Saudi Arabia: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.4.4.1.2.1 Formulation Packaging (ready-to-use)
- 11.4.4.1.2.2 Therapeutic Application
- 11.4.4.1.2.3 Route Of Administration
- 11.4.4.1.2.4 Usability
- 11.4.4.1.2.5 End User
- 11.4.4.2 South Africa Market
- 11.4.4.2.1 South Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.4.2.2 South Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.4.4.2.2.1 Formulation Packaging (ready-to-use)
- 11.4.4.2.2.2 Therapeutic Application
- 11.4.4.2.2.3 Route Of Administration
- 11.4.4.2.2.4 Usability
- 11.4.4.2.2.5 End User
- 11.4.4.3 United Arab Emirates Market
- 11.4.4.3.1 United Arab Emirates: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.4.3.2 United Arab Emirates: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.4.4.3.2.1 Formulation Packaging (ready-to-use)
- 11.4.4.3.2.2 Therapeutic Application
- 11.4.4.3.2.3 Route Of Administration
- 11.4.4.3.2.4 Usability
- 11.4.4.3.2.5 End User
- 11.4.4.4 Rest of Middle East and Africa Market
- 11.4.4.4.1 Rest of Middle East and Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.4.4.2 Rest of Middle East and Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.4.4.4.2.1 Formulation Packaging (ready-to-use)
- 11.4.4.4.2.2 Therapeutic Application
- 11.4.4.4.2.3 Route Of Administration
- 11.4.4.4.2.4 Usability
- 11.4.4.4.2.5 End User
- 11.4.4.1 Saudi Arabia Market
- 11.5 South and Central America
- 11.5.1 South and Central America Long-Term Injectable Drug Delivery Market Overview
- 11.5.2 South and Central America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.5.3 South and Central America: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.5.3.1 Formulation Packaging (ready-to-use)
- 11.5.3.2 Therapeutic Application
- 11.5.3.3 Route Of Administration
- 11.5.3.4 Usability
- 11.5.3.5 End User
- 11.5.4 South and Central America: Long-Term Injectable Drug Delivery Market Breakdown by Countries
- 11.5.4.1 Brazil Market
- 11.5.4.1.1 Brazil: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.5.4.1.2 Brazil: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.5.4.1.2.1 Formulation Packaging (ready-to-use)
- 11.5.4.1.2.2 Therapeutic Application
- 11.5.4.1.2.3 Route Of Administration
- 11.5.4.1.2.4 Usability
- 11.5.4.1.2.5 End User
- 11.5.4.2 Argentina Market
- 11.5.4.2.1 Argentina: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.5.4.2.2 Argentina: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.5.4.2.2.1 Formulation Packaging (ready-to-use)
- 11.5.4.2.2.2 Therapeutic Application
- 11.5.4.2.2.3 Route Of Administration
- 11.5.4.2.2.4 Usability
- 11.5.4.2.2.5 End User
- 11.5.4.3 Rest of South and Central America Market
- 11.5.4.3.1 Rest of South and Central America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.5.4.3.2 Rest of South and Central America: Long-Term Injectable Drug Delivery Market - By Segmentation
- 11.5.4.3.2.1 Formulation Packaging (ready-to-use)
- 11.5.4.3.2.2 Therapeutic Application
- 11.5.4.3.2.3 Route Of Administration
- 11.5.4.3.2.4 Usability
- 11.5.4.3.2.5 End User
- 11.5.4.1 Brazil Market
12. Long-Term Injectable Drug Delivery Market Industry Landscape
13. Long-Term Injectable Drug Delivery Market - Key Company Profiles
- 13.1 Becton Dickinson and Co
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Schott AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Phillips-Medisize
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Gerresheimer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 West Pharmaceutical Services Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Terumo Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 SHL Medical
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Ypsomed Holding AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 AptarGroup Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. List of Additional Companies Analyzed
- 14.1 List of Additional Companies Analyzed
15. Appendix
- 15.1 Glossary
- 15.2 Research Methodology and Approach
- 15.2.1 Secondary Research
- 15.2.2 Primary Research
- 15.2.3 Market Estimation Approach
- 15.2.3.1 Supply Side Analysis
- 15.2.3.2 Demand Side Analysis
- 15.2.4 Research Assumptions and Limitations
- 15.2.5 Currency Conversion
- 15.3 About The Insight Partners
- 15.4 Market Intelligence Cloud
